Skip to main content
REPLIGEN CORP logo

REPLIGEN CORP — Investor Relations & Filings

Ticker · RGEN ISIN · US7599161095 LEI · 54930006QJ0T5AUO1E71 US Manufacturing
Filings indexed 1,023 across all filing types
Latest filing 2026-05-06 Interim / Quarterly Rep…
Country US United States of America
Listing US RGEN

About REPLIGEN CORP

https://www.repligen.com/

Repligen Corporation is a life sciences company that develops and commercializes innovative bioprocessing technologies and systems used in the manufacturing of biologic drugs. The company's portfolio is focused on enhancing efficiency and quality in biopharmaceutical production workflows. Key product areas include filtration, featuring Tangential Flow Filtration (TFF) systems; fluid management, with single-use technologies such as bags, assemblies, and mixers; and process analytics, offering advanced instruments for concentration measurement. Repligen's technologies are integral to the development and cGMP manufacturing of therapies like monoclonal antibodies, vaccines, and cell and gene therapies.

Recent filings

Filing Released Lang Actions
10-Q - REPLIGEN CORP (0000730272) (Filer)
Interim / Quarterly Report
2026-05-06 English
8-K - REPLIGEN CORP (0000730272) (Filer)
Regulatory Filings
2026-05-05 English
SCHEDULE 13G/A - REPLIGEN CORP (0000730272) (Subject)
Major Shareholding Notification
2026-03-27 English
4 - REPLIGEN CORP (0000730272) (Issuer)
Director's Dealing
2026-03-23 English
4 - REPLIGEN CORP (0000730272) (Issuer)
Director's Dealing
2026-03-23 English
4 - REPLIGEN CORP (0000730272) (Issuer)
Director's Dealing
2026-03-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.